Shionogi & Co., Ltd. announced that its group company, Shionogi China Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China for cefiderocol for the treatment of complicated urinary tract infections including pyelonephritis caused by Gram-negative bacteria.
Shionogi Press Release